Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 8/20 | 0.36 |
| ▸ | APP | P05067 | 4/20 | 0.33 |
| ▸ | TYR | P14679 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606789 | 0.99 | COMT (0.37) | COMTAPPTYRHRH3 | |
| SCHEMBL2117671 | 0.81 | TYR (0.43) | COMTAPPTYR | |
| SCHEMBL11926716 | 0.69 | TYR (0.49) | COMTAPPTYR | |
| SCHEMBL7931821 | 0.69 | COMT (0.56) | COMTAPPTYR | |
| SCHEMBL4565634 | 0.68 | TYR (0.49) | COMTAPPTYRHRH3 | |
| SCHEMBL12249894 | 0.68 | TYR (0.36) | COMTTYR | |
| SCHEMBL2117951 | 0.67 | COMT (0.43) | COMTAPPTYR | |
| SCHEMBL24120264 | 0.65 | COMT (0.44) | COMTAPPTYR | |
| SCHEMBL13555556 | 0.65 | TYR (0.41) | COMTAPPTYRHRH3 | |
| SCHEMBL15578471 | 0.63 | MMP1 (0.39) | COMTTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | COMT 695/4885APP 138/4885TYR 1743/4885 |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | SLC40A1, TFRC, FECH | COMT 695/4885APP 138/4885TYR 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.